Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inhibitor of growth protein 2 (ING2)
- Target
- ING2
- Molecular classification
- Transcription factor (chromatin modifier), Histone modification "reader" protein, Tumor suppressor protein
01
Overview
ING2 encodes a nuclear protein that binds to methylated histones (especially H3K4me3) via a plant homeodomain (PHD) zinc finger and is part of the mSin3A/HDAC complex involved in chromatin remodeling and gene repression. It functions primarily as a tumor suppressor by regulating transcription, apoptosis, cellular senescence, and DNA repair. ING2 modulates p53 function, is subject to dynamic regulation via phosphorylation and ubiquitination, and its loss or mislocalization is associated with tumorigenesis. ING2 is implicated in the development and progression of multiple cancers, including colorectal and gynecological cancers, and is being explored as a marker for tumor progression and as a potential therapeutic target through epigenetic and chromatin-targeting strategies.
- Other names
- ING1LING1Lpp33ING2Inhibitor of growth 1-like proteinp32inhibitor of growth family member 2ING2aING2b
02
Mechanism of action
Drugs may alter ING2 function by affecting HDAC/mSin3A complex activity or by targeting chromatin remodeling, though no specific ING2-targeted drug mechanism is validated yet.
03
Biological functions
Chromatin modification and remodelingDNA repairTranscriptional regulationCell cycle regulationCellular senescenceApoptosisTumor suppression
04
Disease associations
Cancer (tumor progression, suppression, context-dependent oncogenesis)Gynecological cancers (e.g., breast, ovarian, endometrial carcinoma)Colorectal cancer
05
Safety considerations
Potential challenges include off-target effects of chromatin-targeting drugs, impact on normal gene expression, and toxicity from altering tumor suppressor pathways
06
Interacting drugs
No approved drugs directly target ING2 to date. Research is ongoing on HDAC inhibitors, chromatin modulators, and other epigenetic therapies exploiting ING2 pathways.
07
Biomarkers
ING2 expression levels are investigated as biomarkers for tumor progression, prognosis, and possibly patient selection in several cancer types
Beyond the preview
Go deeper on Inhibitor of growth protein 2 (ING2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inhibitor of growth protein 2 (ING2).